Neoplasia (New York, N.Y.) · 2011
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.
Оценочное исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shahzad Mian M K, Mangala Lingegowda S, Han Hee Dong, Lu Chunhua, Bottsford-Miller Justin, Nishimura Masato, Mora Edna M, Lee Jeong-Won, Stone Rebecca L, Pecot Chad V, Thanapprapasr Duangmani, Roh Ju-Won, Gaur Puja, Nair Maya P, Park Yun-Yong, Sabnis Nirupama, Deavers Michael T, Lee Ju-Seog, Ellis Lee M, Lopez-Berestein Gabriel, McConathy Walter J, Prokai Laszlo, Lacko Andras G, Sood Anil K
Аннотация
RNA interference holds tremendous potential as a therapeutic approach, especially in the treatment of malignant tumors. However, efficient and biocompatible delivery methods are needed for systemic delivery of small interfering RNA (siRNA). To maintain a high level of growth, tumor cells scavenge high-density lipoprotein (HDL) particles by overexpressing its receptor: scavenger receptor type B1 (SR-B1). In this study, we exploited this cellular characteristic to achieve efficient siRNA delivery and established a novel formulation of siRNA by incorporating it into reconstituted HDL (rHDL) nanoparticles. Here, we demonstrate that rHDL nanoparticles facilitate highly efficient systemic delivery of siRNA in vivo, mediated by the SR-B1. Moreover, in therapeutic proof-of-concept studies, these nanoparticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal transducer and activator of transcription 3 and focal adhesion kinase) in orthotopic mouse models of ovarian and colorectal cancer. These data indicate that an rHDL nanoparticle is a novel and highly efficient siRNA carrier, and therefore, this novel technology could serve as the foundation for new cancer therapeutic approaches.